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aBStract 
Objective: To evaluate the biochemical and nutritional status of smokers in treatment for 
smoking cessation and its association with anthropometric parameters. Methods: This is a 
cross-sectional study with convenience sample. Adult smokers were assessed at the start of 
treatment in the Interdisciplinary Center for Tobacco Research and Intervention of the Univer-
sity Hospital of the Federal University of Juiz de Fora (CIPIT/HU-UFJF). We evaluated the body 
mass index (BMI), conicity index (CI); waist circumference (WC), percentage of body fat (%BF), 
fasting glycemia, cortisol, insulin, total cholesterol (TC), LDL-c, HDL-c, triglycerides (TG) and 
metabolic syndrome (MS). results: Most participants (52.2%) had MS and high cardiovascular 
risk. The fasting glycemia was abnormal in 30.4%. There was a significant positive correlation 
between BMI and WC (r = 0.90; p = 0.0001), %BF (r = 0.79; p = 0.0001), CI (r = 0.65; p = 0.0001), 
glycemia (r = 0.42; p = 0.04) and TG (r = 0.47; p = 0.002). The CI presented positive correction 
with insulin (r = 0.60; p = 0.001), glycemia (r = 0.55; p = 0.007), TG (r = 0.54; p = 0.008) and %BF (r 
= 0.43; p = 0.004). Patients with longer duration of smoking had a higher risk of developing MS 
(OR = 9.6, p = 0.016). conclusion: The smokers evaluated had increased risk for developing 
MS, especially those with longer duration of smoking, requiring urgent smoking cessation. 
reSUMO
Objetivo: Avaliar o perfil bioquímico e nutricional de fumantes em tratamento para a cessa-
ção tabágica e sua associação com parâmetros antropométricos. Métodos: Trata-se de um 
estudo transversal com amostra de conveniência. Adultos fumantes foram avaliados no início 
do tratamento no Centro Interdisciplinar de Pesquisa e Intervenção em Tabagismo do Hospi-
tal Universitário da Universidade Federal de Juiz de Fora (CIPIT/HU-UFJF). Foram avaliados o 
índice de massa corporal (IMC), índice de conicidade (IC), circunferência da cintura (CC), per-
centual de gordura corporal (%GC), glicemia de jejum, cortisol, insulina, colesterol total (TC), 
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colesterol LDL-c, HDL-c, triglicéridos (TG) e síndrome metabólica (SM). resultados: A maioria 
dos participantes possuía SM e alto risco cardiovascular. A glicemia de jejum estava alterada 
em 30,4%. Houve correlação positiva significativa entre IMC e CC (r = 0,90; p = 0,0001), %GC 
(r = 0,79; p = 0,0001), IC (r = 0,65; p = 0,0001), glicemia (r = 0,42; p = 0,04) e TG (r = 0,47; p = 
0,002). O IC também apresentou correlação positiva com insulina (r = 0,6; p = 0,001), glicemia 
(r = 0,55; p = 0,007), TG (r = 0,54; p = 0,008) e %GC (r = 0,43; p = 0,004). Pacientes com maior 
tempo de tabagismo tiveram maior risco de desenvolver SM (O = 9,6; p = 0,016). conclusão: 
Os fumantes avaliados tiveram maior risco de desenvolver SM, especialmente aqueles que 
fumavam por mais tempo, requerendo urgência para a cessação tabágica.
cortisol12,13. In addition, chronic smokers are at increased risk 
for developing insulin resistance and inadequate compensa-
tory response of insulin secretion, which promotes the asso-
ciation of smoking with an increased risk of type 2 diabetes 
mellitus14.
Evaluation of endocrine-metabolic changes that pro-
mote tobacco use, can aid understanding of factors involved 
in the changes of body weight and the development of 
chronic diseases associated with smoking. This article aims to 
evaluate the biochemical and nutritional status of smokers at 
the start of treatment for smoking cessation and its associa-
tion with anthropometric indices.
MetHODS
This is a cross-sectional study with convenience sampling 
conducted in smokers treated in the second half of 2011 by 
the Interdisciplinary Center for Tobacco Research and Inter-
vention of the University Hospital of the Federal University 
of Juiz de Fora (CIPIT/HU-UFJF). We evaluated individuals of 
both sexes, aged between 19 and 59 years who agreed to 
participate and signed the Free and Clarified Consent Term. 
Enrollment for the study was voluntary. Pregnant women, 
nursing mothers and patients with severe psychiatric disor-
der and diseases that interfere with nutritional and metabo-
lic status (infectious, kidney, cardiac, endocrine or liver disea-
ses) were excluded. Pregnant women, breastfeeding women 
and patients with severe psychiatric disorders and diseases 
that interfere with the nutritional and metabolic (infectious, 
renal, cardiac, endocrine or liver disease) were excluded. All 
patients enrolled by CIPIT/HU-UFJF the second half of 2011 
were invited to participate in the study. However, only 30 
smokers effectively started treatment, but only 23 were in-
cluded in this study because of the exclusion criteria. The 
proposal was approved by the Ethics in Research Committee 
of the University Hospital from UFJF (CAAE: 0067.180.420-11).
In the first day of follow-up, clinical history and anthro-
pometric measurements and the degree of nicotine de-
pendence were assessed in each of the smokers for trained 






Smoking represents one of the main modifiable risk factors 
for chronic diseases such as cardiovascular diseases, diabetes 
mellitus and cancer, is considered the most important public 
health problem in the present1. The World Health Organiza-
tion (WHO) estimates that 1.2 billion people are smokers and 
that this number could rise to 1.6 billion in 2030. Total deaths 
worldwide, caused by smoking, are about 5 million a year. 
In Brazil are estimated about 200 000 deaths/year as a result 
of tobacco dependence2. According to the Surveillance Sys-
tem Risk and Protective Factors for Chronic Diseases Survey 
Telephone (VIGITEL), smoking prevalence among the adult 
population of the 27 Brazilian capitals was 14.8%, higher in 
men (18.1%) than in women (12.0%)3. 
The cigarette consists of approximately 4,720 toxic sub-
stances4, and nicotine the main substance responsible for 
tobacco dependence and the development of chronic dis-
eases, particularly cardiovascular disease5. Each cigarette 
contains an average of 7-9 mg of nicotine, of which it is es-
timated that slightly more than 1 mg to be absorbed by the 
smoker4.
Cigarette smoking acts at various levels in the patho-
genesis of chronic diseases, among them the metabolic 
syndrome (MS) and cardiovascular disease6. Risk factors of 
metabolic origin have been described to explain its harmful 
effects on the cardiovascular system, such as hypertension, 
decreased plasma levels of HDL-cholesterol (HDL-C), hyper-
triglyceridemia, impaired fasting glucose and abdominal 
obesity7. According to the Institute of Diabetes Federation8, 
the presence of increased abdominal fat, two risk factors 
listed above characterize the MS and are able to increase the 
overall mortality by 1.5 times and cardiovascular diseases 2.5-
fold5,9.
Endocrine disorders can also be present in smokers and 
corroborate, directly or indirectly to the development of co-
morbidities related to tobacco use. Studies have shown in-
creased plasma levels of cortisol, especially in the first hour 
after smoking10,11. The increase of this hormone is associated 
with changes in body composition and increased visceral fat 
mass, which in turn has an increased number of receptors for 
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Clinical histories were collected type information duration of 
smoking, age at initiation of smoking, number of cigarettes 
smoked per day, among others. Was used the Fagerström 
Nicotine Dependence Test (FNDT) to measure the degree 
of nicotine dependence15,16. The questionnaire has six ques-
tions that are intended to identify the smokers’ behavior, and 
for each question there is a corresponding score. The total 
score obtained in the six responses resulted in a score that 
indicates the degree of dependence: low (0-4 points), mod-
erate (5 points) or high (5-10 points).
Anthropometric nutritional assessment was performed 
at the beginning of the treatment. Body weight (BW), height, 
waist circumference (WC) and abdominal circumference 
(AC) were measured in private rooms and with standardi-
zed protocols17. The BW measurement was performed us-
ing electronic digital balance (Welmy®), and the patient was 
evaluated shoeless and wearing light clothing. Height was 
measured using a stadiometer attached to a balance with 
the patient standing, barefoot, with arms outstretched to the 
sides and heels together, erect head with eyes fixed on the 
horizon, touching the vertical rod of the stadiometer.
To assess the nutritional status, body mass index (BMI) 
was calculated by the formula: BMI = weight (kg)/height 
(m2). The classification was performed as proposed by17, for 
adults, or Lipschitz18, for the elderly patients. The percentage 
of body fat (%BF) was estimated by BMI, using the following 
formulas: Men [%fat = 1.218 (BMI) – 10.13] and women [%fat 
= 1.48 (BMI) – 7]19. The values  obtained were classified ac-
cording to the proposed by Lohman (1991)20.
WC was made with a flexible and inextensible measuring 
tape, with the individual standing, identified the midpoint 
between the last rib and the iliac crest, in the natural curva-
ture. From this point was measured the circumference and 
the reading of the measurement was made at the time of 
expiration17. The interpretation of the results followed the 
cutoffs WC ≥ 90 cm for men and WC ≥ 80 cm for women, 
indicating risk of cardiovascular disease measures that ex-
ceeded these values. AC was measured using flexible and 
inextensible measuring tape encircling the abdomen at the 
umbilicus scar. The conicity index was calculated using the 
equation: CI = waist circumference (m) / [0.109 x (√ P (kg) / 
E (m)] according to the protocol proposed by Valdez21. This 
measure assesses the presence of cardiovascular risk from 
the high cutoff points 1.25 and 1.18 for men and women, 
respectively22.
The Laboratory assessments were performed after the 
participants had fasted overnight, blood samples were 
drawn to measure serum total cholesterol (TC), HDL cho-
lesterol (HDL-C), triacylglycerols (TG), and plasma glucose, 
insulin and cortisol. These tests were performed at the Labo-
ratory of Clinical Analyses of University Hospital of Federal 
University of Juiz de Fora, using specific kits available in the 
laboratory. Glucose tolerance was estimated using the re-
sistance index Homeostasis Model Assessment (HOMA-IR) 
calculated by measuring fasting blood glucose and insulin, 
according to the following formula: [glucose (mmol/L)xinsu-
lin (U/mL)/22.5]23. Insulin resistance was classified individuals 
who had HOMA-IR > 4.6524.
Blood pressure was measured with the patient seated 
after 5 minutes of rest, according to standard procedures, 
being classified as high blood pressure ≥ 130/85 mmHg25.
For all participants, the adult IDF definition of the 
metabolic syndrome was applied26. According to the IDF8 
definition, an individual has the metabolic syndrome if he or 
she has central adiposity plus at least two of the following 
criteria: 1) triglycerides ≥ 150 mg/dL, 2) HDL cholesterol < 40 
mg/dL, 3) systolic blood pressure ≥ 130 mmHg or diastolic 
blood pressure ≥ 85 mmHg, 4) fasting plasma glucose ≥100 
mg/dL or previously diagnosed type 2 diabetes. 
Statistical analysis
Statistical analysis was performed using Epi-Info 6.0 and SPSS 
12.0. First, we conducted a descriptive analysis of the mea-
sured parameters (nutritional status and biochemical tests), 
using mean, standard deviation and maximum and mini-
mum values  of proportion, as the variable type to be descri-
bed. After analysis of the data normality by the Shapiro-Wilk 
comparisons of continuous variables of anthropometry and 
biochemical tests were conducted by nonparametric test 
(Mann-Whitney U test). Categorical variables were compared 
by chi-square. The association between hormone levels and 
the variables of interest was verified by Spearman correla-
tion. We used logistic regression to assess the risk of develo-
ping MS compared to the duration of smoking. In all analyzes 
was considered the significance level of 0.05.
reSUltS
The study involved 23 smokers at the start of treatment. Of 
these, the majority were women (73.9%), with a mean age 
of 43.7 ± 11 years. Of all individuals, 82.6% started smoking 
before adulthood, 69.6% were light smokers, 26.1% modera-
te smokers and 4.3% heavy smokers. The degree of nicotine 
dependence, as measured by the FTND, appeared high in 
65.2% of subjects (Table 1).
The mean BMI was 28.28 ± 6.46 kg/m², of which 65.2% 
were overweight (overweight n = 7 / obesity n = 8) and 
82.6% central obesity from the measurement of WC. The 
presence of MS was seen in 52.2% patients. The IC was used 
as a discriminator for high cardiovascular risk and this was 
found in 52.2% of individuals, and of these, 75% also had MS.
The mean values of cardiovascular and metabolic param-
eters at the beginning of treatment for smoking cessation 
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are shown in table 2. Among the characteristics of smokers 
can observe that the %BF was increased in 69.6% of subjects, 
serum concentrations of TC and LDL-c levels were elevated, 
respectively 52.2% and 78.3% individuals. The HDL-c was be-
low the recommended values  in 65.2% of patients. Hypertri-
glyceridemia was observed in 39.1% subjects. It was found 
impaired fasting glucose 30.4% while 8.7% of patients had 
glucose levels compatible with diabetes (≥ 126 mg/dL). Only 
one individual (4.3%) had serum cortisol and insulin above 
the reference values. The presence of impaired glucose toler-
ance, assessed by HOMA-IR was found in 13% of participants. 
Although the mean values  of systolic and diastolic be within 
the reference values, 30.4% of subjects had increased blood 
pressure.
There was no association between the number of ciga-
rettes/day and the degree of nicotine dependence with 
hormone levels, metabolic and anthropometric parameters. 
However, patients with longer duration of smoking had a 
higher odds of developing MS (OR = 9.6, p = 0.016) (Table 
3). There was a positive correlation between BMI and WC (r 
= 0.90; p = 0.0001), %BF (r = 0.79; p = 0.0001), CI (r = 0.65; p 
= 0.0001), glycemia (r = 0.42; p = 0.04) and TG (r = 0.47; p = 
0.002). The CI presented positive correction with insulin (r = 
0.60; p = 0.001), glycemia (r = 0.55; p = 0.007), TG (r = 0.54; p = 
0.008) and %BF (r = 0.43; p = 0.004). There was also a positive 
correlation between insulin and WC (r = 0.74; p = 0.001) and 
CI (r = 0.60; p = 0.001) (Table 4).
table 1. Characteristics of smoking at the beginning of treatment 
for smoking cessation
Variables n %
Age of onset of smoking
9 a 19 years 19 82.6
20 a 39 years 4 17.4
> 40 years 0 0.0
Total 23 100.0
Number of cigarettes smoked per day
1-20 (Light consumption) 16 69.6
21-40 (Moderate consumption) 6 26.1
> 41 (Heavy consumption) 1 4.3
Total 23 100.0
Duration of smoking
≤ 10 years 3 13.0







table 2. Cardiovascular and metabolic parameters at the 
beginning of treatment for smoking cessation























































Fasting plasma glucose (mg/dL) 98.17 ± 16.10 75 – 140 < 127
HOMA-IR 2.26 ± 1.80 0.66 – 8.00 ≤ 4.65
Insulin (mcIU/mL) 8.77 ± 5.22 2.900 – 25.50 2.60-24.90
Cortisol (mcg/dL) 9.87 ± 4.21 4.1 – 21.80 5-25
table 3. Odds ratio of presence of metabolic syndrome according 
to the duration of smoking
Duration of smoking MS (n) OR P
0-20 years 1 1.00
0.01621-30 years 3 3.30
> 30 years 7 9.63
table 4. Association between anthropometric, biochemical and 
nutritional parameters at the beginning of treatment for smoking 
cessation
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DiScUSSiOn
The results of this study indicate that smokers at initiation of 
treatment had increased risk for developing chronic disea-
ses such as cardiovascular disease, type 2 DM and MS, since 
most of these individuals have changes in lipid profile, in-
crease fasting glucose and blood pressure and overweight 
and obesity abdominal. It was also found that smokers with 
longer smoking had higher odds of developing MS.
The WHO considers smoking as a disease in expansion, 
with a mean age of initiation of 15 years27. The present study 
corroborates this finding, since the average age of smoking 
initiation was found to be 16.35 ± 4.72 years. In study con-
ducted by Prigol et al.5, the degree of nicotine dependence 
was directly related to the age of onset of smoking, and the 
individuals who started smoking before age 20 were classi-
fied with high nicotine dependence, factor related with in-
creased risk of coronary heart disease.
The degree of nicotine dependence, assessed by the 
FTND was high in more than half of the volunteers. However, 
no correlation was found between this variable with none of 
the other variables. Some studies have reported a correlation 
between the number of cigarettes smoked and alteration in 
lipid profile or even on other risk factors associated with MS, 
such as abdominal obesity, increased blood pressure and in-
creased fasting glucose5,28-30. In the present study, this obser-
vation was not found. This finding may be explained by the 
fact that it occurred an evaluation point and not monitoring 
the number of cigarettes smoked over the years. However, 
a positive association was observed between the presence 
of MS and the duration of smoking, which revealed that in-
dividuals who smoke for more than 30 years, possessed 9.6 
times greater risk of developing MS (p = 0.016).
Studies suggest that nicotine promotes increased en-
ergy expenditure and reduces appetite, which explains why 
smokers having a lower BMI than nonsmokers, and the com-
mon weight gain after smoking cessation12,31,32. In contrast, 
it is observed that heavy smokers (> 40 cigarettes/day) tend 
to have higher body weight than light smokers (< 20 ciga-
rettes/day). Suggests that heavy smokers are more likely to 
adopt behaviors that favor weight gain, such as low physical 
activity, low intake of fruits and vegetables and high intake 
of alcohol12. Besides being overweight, these behaviors also 
contribute to the appearance of other cardiovascular risk 
factors such as increased WC, changes in BP and changes in 
lipid and glycemic profiles. In this study there was no correla-
tion between the number of cigarettes smoked per day and 
BMI. However, it should be emphasized again the need for 
an assessment of the number of cigarettes smoked normal-
ly, since it was observed that, when selected for treatment, 
some individuals have reduced the number of cigarettes 
smoked per day.
It is very common to use anthropometric indices to clas-
sify individuals as to the risk of development of chronic de-
generative diseases. In addition to BMI, another index that 
has been used is the IC, an indicator of abdominal obesity 
able to assess the presence of high cardiovascular risk. Ac-
cording Pitanga and Lessa22 the IC can be considered the 
best indicator of high cardiovascular risk when compared to 
WC and BMI, described as intermediate and low discrimina-
tory power of high cardiovascular risk, respectively. In this 
study, more than half (52.1%) of smokers had elevated car-
diovascular risk according to the IC.
BMI showed good association with visceral adiposity, 
%BF, and alterations of plasma glucose and triglycerides. Ac-
cording to Bray and Bellanger33, obesity is a major risk factor 
for cardiovascular disease, diabetes and dyslipidemia, the lat-
ter being characterized by elevated serum TG and low serum 
concentrations of HDL-C. BMI was also associated with IC, in-
dicating a positive correlation between increased body mass 
and increased cardiovascular risk.
In addition to BMI, the IC was correlated with insulin, 
glucose, triglycerides and the %BF. Why be an indicator of 
abdominal obesity, it is expected that this index shows a 
positive correlation with these variables. Moreover, visceral 
adipose tissue increases the plasma concentrations of free 
fatty acids in plasma, and these increase hepatic glucose pro-
duction, inhibit insulin action in the liver28 and increase the 
production of very low density lipoprotein (VLDL)13. Studies 
indicate increased levels of blood pressure in smokers com-
pared with nonsmokers28,34. In this study, the prevalence of 
change in blood pressure was 30.4%. In cross-sectional study 
by Nakashita et al.29, the prevalence of hypertension in light 
smokers (< 20 cigarettes/day) was 51%.
Of all patients, over 90% had some type of alteration 
lipid profile, being common association between increased 
plasma levels of LDL-C and decreased HDL-c (52%). These 
changes are usually associated with increased sympathetic 
activity caused by nicotine28 and represent a future risk for 
the onset of atherosclerosis, being more significant in chron-
ic smokers5. The abdominal obesity shown in smokers may 
also contribute to the increased incidence of dyslipidemia, 
since the increase in visceral adiposity is associated with 
increased plasma lipoprotein9,35. Thus, the high percentage 
of abdominal obesity found may be related to changes ob-
served in the lipid profile.
Regarding glucose, it was observed that although the 
mean values  were within the normal range, about a third 
(30.4%) patients had blood glucose greater than or equal 
to 100 mg/dL. Nakashita et al.29 in cross-sectional study with 
Japanese subjects, found a prevalence of 5.1% in cigarette 
smokers. Studies indicate that tobacco use has been associ-
ated with reduced insulin sensitivity and development of in-
Hormonal-metabolic alterations in smoker
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sulin resistance28, promoting glucose metabolism disorders, 
leading to hyperglycemia14.
Serum concentrations of the hormones insulin and corti-
sol were increased in only one smoker. Chiolero et al.12 report-
ed that in healthy men, chronic smoking is associated with 
increased insulin levels, independent of other factors known 
to influence the sensitivity to this hormone. Although serum 
cortisol did not increase in most patients evaluated in this 
study, other authors have shown that smoking increases cir-
culating levels of this hormone and others such as catechol-
amines, and growth hormone actions that are antagonistic 
to insulin and may contribute to insulin resistance and higher 
blood glucose levels between smokers28,36. Excess abdominal 
fat may also explain the occurrence of IR, since the present 
study showed a correlation between insulinemia and WC.
There is evidence that smoking leads to an increase in 
visceral fat mass, which is influenced by the concentration 
of cortisol12,28,29. One of the characteristics of this hormone is 
increased lipogenesis in visceral adipose tissue13. Other stud-
ies have shown increased levels of this hormone in smok-
ers, especially in the first hour after smoking10,11. Although 
the analysis of these hormones have been performed in the 
morning (fasting), a limiting factor for the result was the lack 
of standardization between the time of the last cigarette and 
examination.
The main limitation of this study was to have a cross-sec-
tional design and evaluation of one group of smokers, which 
affects the interpretation of results, since the small sample of 
patients and absence of a temporal sequence that prevents 
establish causal links between exposure and disease devel-
opment factor. Moreover, the absence of a control group 
was a factor that prevented comparisons were made with 
data from healthy individuals of the same sex and age. How-
ever, the study will be continued to compare the changes 
that were observed at the beginning with the changes at 
the end of treatment. For this analysis there is no need for a 
control group. However, the study was positive in indicating 
the urgency of smoking cessation, confirming the harmful 
effects of tobacco on the health of these individuals, and in-
dicates the need for multidisciplinary team in the treatment 
of smokers. 
In conclusion, the smokers evaluated at the beginning 
of treatment for smoking cessation have changes in lipid 
profile, increased fasting glucose, increased blood pressure, 
overweight and abdominal obesity, which may contribute 
to the development of chronic diseases, particularly cardio-
vascular diseases, type 2 DM and MS. Regardless of the num-
ber of cigarettes smoked per day, the profile of smokers had 
evaluated increased risk for developing MS, especially those 
with longer duration of smoking. Smokers require urgently 
for smoking cessation, to prevent metabolic complications 
associated with tobacco use. These results reinforce the im-
portance of the multidisciplinary team involved in treatment 
strategy, aimed not only smoking cessation as well as pre-
vention of diseases associated with smoking and improving 
the quality of life.
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